CDSCO Approval granted for Early Cancer Detection Test

This exceptional performance indicates the test's ability to accurately cancer detection while minimizing the risk of false positives.

The Health Master

April 8, 2024

693

CDSCO Central Drug Standard Control Organisation — CDSCO

Table of Contents

Last Updated on April 18, 2024 by The Health Master

Cancer Detection

ErlySign, a pioneering biotech startup, has achieved a major milestone in the fight against cancer by means of Early Cancer Detection Test.

The Central Drugs Standard Control Organisation (CDSCO), India’s leading regulatory body, has granted approval for ErlySign’s innovative active salivary biomarker study designed for early cancer detection.

This marks a significant step forward in the development of a potentially life-saving diagnostic tool.

Follow us on WhtasApp Channel

CDSCO Approval for Large-Scale Clinical Trials

Following a rigorous year of evaluation and analysis of in-house data from 150 test samples, the CDSCO has greenlit ErlySign to proceed with large-scale clinical trials.

These trials will play a crucial role in further validating the effectiveness of the company’s technology and paving the way for wider clinical adoption.

Early Studies Show Promising Results

Initial studies of the active salivary biomarker test have yielded highly encouraging results.

The test demonstrated an impressive sensitivity of 98% and an unmatched specificity of 100%.

This exceptional performance indicates the test’s ability to accurately cancer detection while minimizing the risk of false positives.

Click for more articles on CDSCO

Revolutionizing Cancer Detection with Patented Technology

ErlySign’s proprietary technology has the potential to revolutionize cancer screening.

The company holds patents in both the US and India for its oral cancer detection kit, showcasing its commitment to advancing early-stage cancer diagnosis. Furthermore, ErlySign is actively developing a lung cancer detection kit, highlighting its dedication to expanding its cancer screening solutions.

Faster and More Efficient Testing

ErlySign recently introduced an innovative automated multi-sample reader for its oral cancer detection kit.

This reader streamlines the testing process, enabling the processing of multiple samples within a timeframe of just 15-20 minutes. This rapid turnaround time could significantly improve patient convenience and expedite diagnosis.

Click for more articles on DCGI

Empowering Early Detection and Treatment

“Our technology empowers individuals to detect pre-cancerous conditions even before the emergence of any oral lesions or tumors,” says Shubhendra Singh Thakur, CEO of ErlySign. “This allows for proactive intervention and potentially saves countless lives.”

Early Cancer Risk Assessment Through Saliva Analysis

The oral cancer detection kit utilizes a semi-quantitative approach, analyzing saliva biomarkers to assess pre-cancerous conditions.

The test results are categorized as low, moderate, or high risk, providing individuals with valuable insights into their personal cancer risk profile.

This information can prompt necessary follow-up consultations and early treatment, potentially leading to improved patient outcomes.

ErlySign’s advancements in early cancer detection hold immense promise for the future of cancer management.

The company’s dedication to developing accurate, efficient, and accessible diagnostic tools has the potential to empower individuals with crucial knowledge about their health and contribute significantly to the fight against cancer.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.